These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 26078965)

  • 1. Advances in Development of New Treatment for Leishmaniasis.
    de Menezes JP; Guedes CE; Petersen AL; Fraga DB; Veras PS
    Biomed Res Int; 2015; 2015():815023. PubMed ID: 26078965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease inhibitors in potential drug development for Leishmaniasis.
    Das P; Alam MN; Paik D; Karmakar K; De T; Chakraborti T
    Indian J Biochem Biophys; 2013 Oct; 50(5):363-76. PubMed ID: 24772958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA topoisomerases of Leishmania: the potential targets for anti-leishmanial therapy.
    Das BB; Ganguly A; Majumder HK
    Adv Exp Med Biol; 2008; 625():103-15. PubMed ID: 18365662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential therapeutic targets and the role of technology in developing novel antileishmanial drugs.
    Rajasekaran R; Chen YP
    Drug Discov Today; 2015 Aug; 20(8):958-68. PubMed ID: 25936844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of biochemically characterized drug targets in metabolic pathways of Leishmania parasite.
    Raj S; Sasidharan S; Balaji SN; Saudagar P
    Parasitol Res; 2020 Jul; 119(7):2025-2037. PubMed ID: 32504119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.
    Tiwari N; Gedda MR; Tiwari VK; Singh SP; Singh RK
    Mini Rev Med Chem; 2018; 18(1):26-41. PubMed ID: 28443518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity.
    Sharlow ER; Leimgruber S; Murray S; Lira A; Sciotti RJ; Hickman M; Hudson T; Leed S; Caridha D; Barrios AM; Close D; Grögl M; Lazo JS
    ACS Chem Biol; 2014 Mar; 9(3):663-72. PubMed ID: 24328400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conventional Versus Natural Alternative Treatments for Leishmaniasis: A Review.
    Passero LFD; Cruz LA; Santos-Gomes G; Rodrigues E; Laurenti MD; Lago JHG
    Curr Top Med Chem; 2018; 18(15):1275-1286. PubMed ID: 30277153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug search for leishmaniasis: a virtual screening approach by grid computing.
    Ochoa R; Watowich SJ; Flórez A; Mesa CV; Robledo SM; Muskus C
    J Comput Aided Mol Des; 2016 Jul; 30(7):541-52. PubMed ID: 27438595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug delivery: lessons to be learnt from Leishmania studies.
    Shaw CD; Carter KC
    Nanomedicine (Lond); 2014 Jul; 9(10):1531-44. PubMed ID: 25253500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing of known drugs for leishmaniasis treatment using bioinformatic predictions, in vitro validations and pharmacokinetic simulations.
    Bustamante C; Ochoa R; Asela C; Muskus C
    J Comput Aided Mol Des; 2019 Sep; 33(9):845-854. PubMed ID: 31612362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The enemy within: Targeting host-parasite interaction for antileishmanial drug discovery.
    Lamotte S; Späth GF; Rachidi N; Prina E
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005480. PubMed ID: 28594938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of leishmaniasis: a review and assessment of recent research.
    Elmahallawy EK; Agil A
    Curr Pharm Des; 2015; 21(17):2259-75. PubMed ID: 25543123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear DNA replication and repair in parasites of the genus Leishmania: Exploiting differences to develop innovative therapeutic approaches.
    Uzcanga G; Lara E; Gutiérrez F; Beaty D; Beske T; Teran R; Navarro JC; Pasero P; Benítez W; Poveda A
    Crit Rev Microbiol; 2017 Mar; 43(2):156-177. PubMed ID: 27960617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in Nanosystems and Strategies for Managing Leishmaniasis.
    Vaghela R; Kulkarni PK; Osmani RAM; Bhosale RR; Naga Sravan Kumar Varma V
    Curr Drug Targets; 2017; 18(14):1598-1621. PubMed ID: 27033193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fishing for anti-leishmania drugs: principles and problems.
    Handman E; Kedzierski L; Uboldi AD; Goding JW
    Adv Exp Med Biol; 2008; 625():48-60. PubMed ID: 18365658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulation by chemotherapeutic agents against Leishmaniasis.
    Saha P; Mukhopadhyay D; Chatterjee M
    Int Immunopharmacol; 2011 Nov; 11(11):1668-79. PubMed ID: 21875692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-leishmanial Nanotherapeutics: A Current Perspective.
    Shah A; Gupta SS
    Curr Drug Metab; 2019; 20(6):473-482. PubMed ID: 30360732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (Post-) Genomic approaches to tackle drug resistance in Leishmania.
    Berg M; Mannaert A; Vanaerschot M; Van Der Auwera G; Dujardin JC
    Parasitology; 2013 Oct; 140(12):1492-505. PubMed ID: 23480865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physicochemical characterization by AFM, FT-IR and DSC and biological assays of a promising antileishmania delivery system loaded with a natural Brazilian product.
    Marquele-Oliveira F; Torres EC; Barud Hda S; Zoccal KF; Faccioli LH; Hori JI; Berretta AA
    J Pharm Biomed Anal; 2016 May; 123():195-204. PubMed ID: 26897464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.